Company intelligence / Profile preview

Electrabel

South San Francisco, California, United States

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Electra Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies that target the Signal Regulatory Protein (SIRP) pathway to treat immunological diseases and cancer. The company's lead candidate, ELA026, is a monoclonal antibody targeting SIRP-alpha and SIRP-gamma, currently in clinical trials for secondary Hemophagocytic Lymphohistiocytosis (sHLH). By modulating the SIRP pathway, Electra aims to regulate the activity of myeloid cells and T cells to restore immune balance. The company was founded by industry veterans and is backed by prominent life science investors to advance its pipeline of targeted immunotherapies.

Therapeutic areas: HematologyOncology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Electrabel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Electrabel.

Explore the full profile